Regular treatment with salmeterol and inhaled steroids for chronic asthma: Serious adverse events

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Cates, Christopher J ^a   Lasserson, Toby J ^a   Jaeschke, Roman ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; SALMETEROL; STEROID; FORMOTEROL; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DRUG DERIVATIVE; SALBUTAMOL;

AIRWAY OBSTRUCTION; ASTHMA; CELL HETEROGENEITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MEDICAL RESEARCH; MORTALITY; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CINAHL; CLINICAL ASSESSMENT; COCHRANE LIBRARY; DATA BASE; DATA EXTRACTION; EMBASE; FOLLOW UP; INHALER; MEDLINE; OUTCOME ASSESSMENT; PSYCINFO; SYSTEMATIC REVIEW; TREATMENT DURATION; ADOLESCENT; ADULT; CHILD; META ANALYSIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; HUMANS; YOUNG ADULT;

EID: 70049106524     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006922.pub2     Document Type: Review

References (233)

1. SFCB3019. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SFCB3019.pdf Accessed July 2008.
2. Aubier M, Pieters WR, Schlösser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respiratory Medicine 1999;93:876-884
3. SFCB3022 . http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SFCB3022.pdf Accessed July 2008.
4. * Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 micrograms twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respiratory Medicine 2001;95:136-146
5. Anonymous. GSK asthma trial suggests total control is possible. Pharmaceutical Journal 2004;273(7322):594.
6. Arthurs R. Gaining optimal asthma control. Practice Nurse 2004; Suppl:3-8.
7. Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R, Pedersen S. Achieving and maintaining guideline defined asthma control with salmeterol/fluticasone propionate versus fluticasone propionate alone: the results of the GOAL study. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A87.
8. Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R, Pederson S. Achievement for guideline based asthma control with salmeterol/fluticasone proprioante comapred with fluticasone proprioante alone; Results of Goal study. Triennial World Asthma Meeting, Thailand (16-19 February). 2004.
9. Bateman E, Pauwels R, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Aiming for total control of asthma significantly improves asthma-related quality of life: salmeterol/fluticasone propionate versus fluticasone propionate alone. Amercian Journal of Respiratory and Critical Care Medicine 2004;169(7):A87.
10. * Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, GOAL Investigators Group. Can guideline- defined asthma control be achieved? The Gaining Optimal Asthma ControL study. American Journal of Respiratory & Critical Care Medicine 2004;170(8):836-844
11. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, GOAL Investigators Group. Can guideline- defined asthma control be achieved? The Gaining Optimal Asthma ControL study. American Respiratory and Criticial Care Medicine. 2004:Online data supplement.
12. Bateman ED, Bousquet J, Keech ML, Busse WW, Clark TJ, Pedersen SE. The correlation between asthma control and health status: the GOAL study. European Resspiratory Journal 2006:Epub ahead of print. (Pubitemid 43920150)
13. Bateman ED, Edin HM, Sondhi S, Gul N. Asthma-related quality of life in the GOAL study: Baseline results. European Respiratory Journal 2002;20(Suppl 38):46s.
14. Bons J, Cordier JF, Godard P, Prud'Homme A, Celli I, Bousquet J. Aiming for total control of asthma: the GOAL study design. Revue Française d'Allergologie et d'Immunologie Clinique 2004;44(367): TT13.
15. Boushey H, Bateman E, Bousquet J, Busse W, Clark T, Pauwels R, Pedersen S. Improvements in asthma outcomes following 1 year of treatment with salmeterol/fluticasone or fluticasone alone when stepped up to achieve guideline-defined total control. Journal Allergy and Clinical Immunology 2004;113(2 (suppl 1)):114s-5s.
16. Boushey H, Bateman E, Bousquet J, Busse W, Clark T, Pauwels R, Pederson S. Achieving total control of asthma with salmeterol/fluticasone propionate versus fluticasone propionate alone: Goal study results. Triennial World Asthma Meeting, Thailand (16-19 February). 2004.
17. Boushey HA, Pedersen S, Bateman E, Clark T, Busse W, Bousquet J, Pauwels R. Improved exacerbation rates and asthma control in current and former smokers treated with salmeterol/fluticasone propionate: results of the GOAL study. Journal of Allergy & Clinical Immunology 2005;115(Suppl 2):S59.
18. Bousquet J. Is asthma control achievable?. European Respiratory Review 2004;13(92):102-104
19. Bousquet J, Bateman E, Boushey H, Busse W, Clark T, Pauwels R, Pedersen S. The effect of oral corticosteroids and high-dose combination therapy on achieving control of refractory asthma. Journal Allergy and Clinical Immunology 2004;113(2 (suppl 1)):113s.
20. Bousquet J, Bons J, Godard P, Cordier JF, Desfougeres JL, Prud'Homme A. Aiming for total control of asthma: the GOAL study results. Revue Française d'Allergologie et d'Immunologie Clinique 2004;44(367):TT16.
21. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJH, Pedersen SE, Bateman ED. Cost-effectiveness of asthma control: An economic appraisal of the GOAL study. Allergy 2006;61(5):531-536
22. Busse W, Bateman E, Boushey H, Bousquet J, Clark T, Pauwels R, Pedersen S. Achieving GINA/NIH guideline-based asthma control with salmeterol/fluticasone compared with fluticasone alone: the results of the GOAL study. Journal of Allergy and Clinical Immunology 2004;113(2 (suppl 1)):114s.
23. Busse W, Bateman E, Boushey H, Bousquet J, Clark T, Pauwels R, Pederson S. Aiming to achieve total control of asthma with salmeterol/luticaosne proprioante and flutiasone proprioante alone is well tolerated: Goal 1 year safety data. Triennial World Asthma Meeting, Thailand (16-19 February). 2004.
24. Clark T, Bateman E, Boushey H, Bousquet J, Busse W, Pauwels R, Pedersen S. Salmeterol/fluticasone and fluticasone alone are well tolerated over 1 year of treatment stepped-up to achieve total control: safety results of the GOAL study. Journal Allergy and Clinical Immunology 2004;113(2 (suppl 1)):115s.
25. Clark T, Bateman E, Boushey H, Bousquet J, Busse W, Pauwels R, Pedersen S. Time course of achievement of individual clinical goals of asthma treatment: the results of the GOAL study. Amercian Journal of Respiratory and Critical Care Medicine 2004;169(7):A318.
26. Clark TJ, Bousquet J, Bateman ED, James MH. GOAL (gaining optimal asthma control): a study to assess asthma control. European Respiratory Journal 2001;18(Suppl 33):175-6s.
27. Clark TJH, Bateman ED, James MH, on behalf of the GOAL Steering Committee. Assessing asthma control using a composite measure based on GINA/NIH guidelines: an analysis of GOAL baseline data. European Respiratory Journal 2002;20(Suppl 38):47s.
28. Clark TJH, Bateman ED on behalf of the GOAL Steering Committee. Aiming for Total Control of asthma in ICS-free patients improves traditional outcomes: Results of the Gaining Optimal Asthma controL (GOAL) study [abstract]. 23rd European Academy of Allergology and Clinical Immunology Meeting Abstract Book. June 12-16. Amsterdam, The Netherlands. 2004; Vol.204:669.
29. Cordier JF, Bousquet J, Boucot I, Prud'Homme A, Godard P. Which dose for achieving total control of asthma? The results of the GOAL study. Revue Française d'Allergologie et d'Immunologie Clinique 2004; 44(367):TT14.
30. Godard P, Prud'Homme A, Cordier JF, Sohier B, Bousquet J. Time course of achievement of asthma control: The results of the GOAL study. Revue Française d'Allergologie et d'Immunologie Clinique 2004; 44(367):TT15.
31. Juniper EF, Bateman ED, Sondhi S, Gul N. Asthma Control Questionnaire (ACQ) differentiates between levels of clinical control in a large scale trial. Amercian Journal of Respiratory and Critical Care Medicine 2003;167(7):A37.
32. Pauwels R, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Addition of oral corticosteroids to combination therapy has little impact on achieving total control of asthma.. 4th Triennial World Asthma Meeting Abstract Book, Bangkok, Thailand, February 16-19. 2004:135.
33. Pauwels R, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Aiming for total control of asthma reduces the risk of exacerbations: a comparison of salmeterol/fluticasone propionate versus fluticasone propionate alone. American Journal of Respiratory and Critical Care Medicine 2004;169(7):A87.
34. Pauwels R, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pedersen S. Can total control of asthma be achieved?: the results of the GOAL study. Journal of Allergy and Clinical Immunology 2004; 113(2 (suppl 1)):114s.
35. Pedersen SE. Is guideline-defined asthma control achievable? The Gaining Optimal Asthma ControL (GOAL) Study [Er guideline- defineret astmakontrol opnaelig?]. Ugeskrift for Laeger 2005;167 (38):3595-3597
36. Pedersen SE, Bateman ED on behalf of the GOAL Steering Committee. Aiming for Total Control of asthma in patients taking inhaled corticosteroids improves traditional outcomes: Results of the Gaining Optimal Asthma controL (GOAL) study. [abstract]. 3rd European Academy of Allergology and Clinical Immunology Meeting Abstract Book. June 12-16. Amsterdam, The Netherlands. 2004; Vol.204:670.
37. Pederson S, Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R. Aiming for guideline defined total control of asthma improves one-year asthma outcomes:Results of Goal study. Triennial World Asthma Meeting, Thailand (16-19 February). 2004.
38. SAM40027. Gaining Optimal Asthma ControL (GOAL): A multi-centre, stratified, randomised, double-blind, parallel-group, step-up comparison of the level of asthma control achieved with salmeterol/fluticasone propionate combination DISKUS (ACCUHALER) dry powder inhaler compared with fluticasone propionate DISKUS (ACCUHALER) alone in adults and adolescents. http://www.ctr.gsk.co.uk 2004.
39. SLGQ97 (SLGB4010). http: //ctr.gsk.co.uk/Summary/salmeterol/IV-SLGB4010. pdf Accessed July 2008.
40. Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respiratory Medicine 2003;97:555-562 (Pubitemid 36519529)
41. SFCA3002. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SFCA3002.pdf Accessed July 2008.
42. * Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 150(6):1108-1116
43. SAM40086. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAM40086.pdf Accessed July 31 2008.
44. Koenig SM, Murray JJ, Wolfe J, Andersen L, Yancey S, Prillaman B, et al. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?. Respiratory Medicine 2008;102:665-673
45. SAS30013. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAS30013.pdf accessed August 11 2008.
46. Koopmans JG, Lutter R, Jansen HM, van der Zee JS. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 2006;61:306-312
47. FAS40008. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- FAS40008-1y.pdf accessed August 11th 2008.
48. Lundbäck B, Rönmark E, Lindberg A, Jonsson AC, Larsson LG, Pétavy F, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respiratory Medicine 2006;100:2-10.
49. SAS30031. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30031.pdf Accessed July 2008.
50. * Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005;96:66-71.
51. SAS30017. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30017.pdf Accessed July 2008.
52. * Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol. 2004;93:351-9 2004;93:351-359
53. Edin HM, Payne E, Herrle MR, Schoaf L, Mather DB, Scott CA, et al. Salmeterol/fluticasone propionate combination via HFA MDI improves quality of life. Journal of Allergy & Clinical Immunology 2001;107(2):S246.
54. Nathan RA, Mitchell D, Condemi J, Heller A, Schoaf L, Herrle M, et al. Cardiovascular and hypothalmic-pituitary-adrenal axis safety of fluticasone propionate/salmeterol HFAMDI in adolescent and adult patients with asthma. American Journal for Respiratory and Critical Care Medicine 2001;163(5):A863.
55. * Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12- week study. Clinical therapeutics 2006;28(1):73-85.
56. Pearlman DS, Kent E, Lanz MJ, Peden D, Baitinger L, Herrle M, et al. Fluticasone propionate/salmeterol HFA MDI has a rapid onset of effect in asthmatics treated with short or long-acting beta-agonists (BA) or inhaled corticosteroids (ICS). Amercian Journal of Respiratory and Critical Care Medicine 2001;163(5):A865.
57. Rooklin A, Elkayam D, Weiler J, Windom H, Schoaf L, Scott C, et al. The fluticasone propionate/salmeterol HFA MDI is significantly more efficacious in treating asthma than placebo HFA MDI, fluticasone propionate CFC MDI or salmeterol CFC MDI. Journal of Allergy and Clinicial Immunology 2001;107(2):100s.
58. SAS30004. A randomized, double-blind, placebo-controlled, parallel- group 12-week trial evaluating the safety and efficacy of the salmeterol/ fluticasone propionate combination in GR106642X MDI, 50/250mcg BID, and salmeterol in propellant 11/12 MDI, 50mcg BID, fluticasone propionate in propellant 11/12MDI, 250mcg BID, and placebo propellant GR106642X MDI in adult and adolescent subjects with asthma. http://ctr.gsk.co.uk 2005.
59. SAS30001. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30001.pdf Accessed July 2008.
60. * Nelson HS, Wolfe JD, Gross G, Greos LS, Baitinger L, Scott C, Dorinsky P. Efficacy and safety of fluticasone propionate 44mcg/salmeterol 21mcg administered in a hydrofluoroalkane (HFA) metered dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 2003;91:263-269
61. * Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. Journal of Asthma 2004;41(8):797-806.
62. SAS30003. A stratified, randomised, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the safety and efficacy of the salmeterol/fluticasone propionate combination in HFA 134a MDI, 42/88mcg BID, and salmeterol in propellant 11/12 MDI, 42mcg BID, fluticasone propionate in propellant 11/12 MDI, 88mcg BID, and placebo propellant HFA 134a MDI in adult and adolescent subjects with asthma. http://ctr.gsk.co.uk 2005.
63. Weinstein SF, Pearlman DS, Condemi JJ, Herrle MR, Scott CA, Payne JE, et al. Superior efficacy of the fluticasone propionate/salmeterol 88/42mcg HFA-MDI combination product versus the individual components in asthmatics previously treated with either short- or long-acting beta2-agonists or inhaled corticosteroids. Journal of Allergy & Clinial Immunology 2001;107(2):S102.
64. SAS30039. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30039.pdf Accessed July 2008.
65. Barnes N, Rojas R, Palga I, Goldfrad C, Duggan M. Efficacy and safety of fluticasone propionate/salmeterol (250/50ug bd) in a single diskus device compared with fluticasone propionate diskus alone (250ug) as initial maintenance therapy in moderate asthma [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[B35] [Poster: G13].
66. * Rojas RA, Paluga I, Goldfrad CH, Duggan MT, Barnes N. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. J Asthma 2007;44:437-441
67. SAM30007. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAM30007.pdf.
68. * SAM40004. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV-SAM40004.pdf accessed August 19 2008.
69. SAM40008. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAM40008.pdf.
70. SAM40012. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAM40012.pdf.
71. SAM40031. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAM40031.pdf.
72. SAM40065. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAM40065.pdf accessed august 11th 2008.
73. SAS30021. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30021.pdf accessed August 11th 2008.
74. SAS30022. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30022.pdf Accessed July 2008.
75. Kerwin EM, Nathan RA, Meltzer EO, Ortega HG, Yancey SW, Schoaf L, et al. Efficacy and safety of fluticasone propionate/ salmeterol 250/50mcg Diskus administered once daily. Respir Med. 2008/01/22 2008; Vol.102, issue 4:495-504. [0954-6111: (Print)]
76. SAS30023. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30023.pdf accessed August 11 2008.
77. Boonsawat W, Goryachkina L, Millns H, Balsara S. The efficacy and safety of seretide/advair once daily (50/100 mcg) compared with fluticasone propionate (100mcg) once daily and placebo as initial maintainence therapy inmild asthma [Abstract]. American Thoracic Society 100th International Conference, May 21-26, 2004, Orlando 2004:A37 Poster J82.
78. SAS40036. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAS40036.pdf accessed August 11th 2008.
79. SAS40037. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAS40037.pdf accessed August 11 2008.
80. SAS40068. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAS40068.pdf Accessed August 11 2008.
81. SFA103153. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SFA103153.pdf Accessed July 2008.
82. Bailey W, Castro M, Matz J, White M, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone proprionate and salmeterol or fluticasone proprionate alone. Current Medical Research and Opinions 2008;24(6):1669-1682 (Pubitemid 351929065)
83. SFCF4026. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SFCF4026.pdf Accessed August 11 2008.
84. SFCA3003. A Randomized, Double-Blind, Parallel-Group Trial Evaluating Safety and Efficacy of Salmeterol 50mcg BID and Fluticasone Propionate 250mcg BID Individually and in Combination and Placebo in Subjects with Asthma. http://ctr.gsk.co.uk/Summary/fluticasone-salmeterol/III-SFCA3003.pdf 2005.
85. Shapiro G, Lumry W, Wolfe J, Given J, White M, Woodring A, et al. Combined salmeterol 50mcg and fluticasone propionate 250mcg in the diskus device for the treatment of asthma. American Journal of Respiratory and Critical Care Medicine 2000;161:527-534 (Pubitemid 30129463)
86. SLGF75. http://ctr.gsk.co.uk/Summary/fluticasone- propionate/IV-SLGF75. pdf Accessed August 11th 2008.
87. SAM40049. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAM40049.pdf Accessed July 2008.
88. Strand AM, Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respiratory Medicine 2004;98:1008-1015 (Pubitemid 40029132)
89. SFCB3023. http://ctr.glaxowellcome.co.uk/Summary/fluticasone- salmeterol/III-SFCB3023.pdf Accessed July 2008.
90. * van Noord JA, Lill H, Carrillo Diaz C, Greefhorst AP, Davies P. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500 mcg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus™ in patients with moderate to severe asthma. Clin Drug Investig 2001;21:243-255. 2001;21: 243-255
91. SLGQ98. http://ctr.gsk.co.uk/Summary/salmeterol/IV- SLGQ98.pdf Accessed July 2008.
92. Wallin A, Sue-Chu M, Bjermer L, Ward J, Sandström T, Lindberg A, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 2003;112: 72-78 (Pubitemid 36819810)
93. Adinoff AD, Schwartz HJ, Rickard KA, Yancey SW, Swearingen BE. Salmeterol compared with current therapies in chronic asthma.[erratum appears in J Fam Pract 1999 Jan;48(1):67]. Journal of Family Practice 1998; Vol.47, issue 4:278-284
94. Adolfsson LE, Lundgren M, Tilling B, Jern S, Tyren C, Godwood A, et al. Short-term safety and tolerability of double-dose salmeterol/ fluticasone propionate in adult asthmatic patients. Clinical Drug Investigation 2005; Vol.25, issue 4:231-241 (Pubitemid 40593610)
95. Bateman ED, Britton M, Carrillo J, Almeida J, Wixon C. Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clinical Drug Investigation 1998; Vol.16, issue 3:193-201.
96. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/ salmeterol in a single inhaler is stepped down. Journal of Allergy & Clinical Immunology 2006; Vol.117, issue 3:563-570 (Pubitemid 43340219)
97. Baumgarten C, Geldszus R, Behre U, Peslis N, Trautmann M. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). Eur J Med Res 2002; Vol.7, issue 1:1-7.
98. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/ fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Medical Weekly 2004; Vol.134, issue 3-4:50-58 (Pubitemid 38139882)
99. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahtela T, et al. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, doubleblind comparative study the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial. Respiratory Medicine 2000; Vol.94, issue 6:612-621 (Pubitemid 30601338)
100. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; Vol.327, issue 7420:891. (Pubitemid 37289961)
101. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, et al. Salmeterol response is not affected by beta2- adrenergic receptor genotype in subjects with persistent asthma. Journal of Allergy & Clinical Immunology 2006; Vol.118, issue 4: 809-816 (Pubitemid 44498754)
102. Bleecker E, Yancey S, Ortega H, Anderson W. Arginine 16 genotype does not modulate clinical response to salmeterol in subjects with asthma. Chest 2007; Vol.132, issue 4:436.
103. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to long-acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.[see comment]. [Review] [33 refs] Comment in: Lancet. 2008 Dec 22;370(9605):2075-6; PMID: 18156014. LANCET 2008; Vol.370, issue 9605:2118-2125
104. Bracamonte T, Schauer U, Emeryk A, Godwood A, Balsara S. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus or pressurised metered-dose inhaler in children with asthma. Clinical Drug Investigation 2005; Vol.25, issue 1:1-11. (Pubitemid 40070108)
105. Busse W. The effect of salmeterol on eosinophil function. clinicaltrials. gov 2006.
106. Calhoun WJ, Nelson HS, Nathan RA, Pepsin PJ, Kalberg C, Emmett A, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta2-agonists alone. American Journal of Respiratory & Critical Care Medicine 2001; Vol.164, issue 5:759-763 (Pubitemid 32881910)
107. Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate 50/250 mug administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers. Canadian Respiratory Journal 1999; Vol.6, issue 1:45-51.
108. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Annals of Allergy, Asthma, & Immunology 1999; Vol.82, issue 4:383-389 (Pubitemid 29203287)
109. Cook D, Srebro SH, Rogenes PR, Rickard K, Edwards L, Johnson MC. A comparison of the safety and efficacy of fluticasone, triamcinolone, and fluticasone plus salmeterol in patients with mild to moderate asthma [abstract]. American Journal of Respiratory and Critical Care Medicine 1998; Vol.157, issue 3 Suppl:A416. (Pubitemid 28285669)
110. D'Urzo AD, Chapman KR, Cartier A, Hargreave FE, Fitzgerald M, Tesarowski D. Effectiveness and safety of salmeterol in non-specialist practice settings. Chest 2001; Vol.119, issue 3:714-719 (Pubitemid 32197638)
111. Del Rio-Navarro BE, Sienra-Monge JJL, Alvarez-Amador M, Reyes- Ruiz N, Arevalo-Salas A, Berber A. Serum potassium levels, CPK-MB and ECG in children suffering asthma treated with beclomethasone or beclomethasone-salmeterol. Allergologia et Immunopathologia 2001; Vol.29, issue 1:16-21.
112. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. American Journal of Respiratory & Critical Care Medicine 2007; Vol.175, issue 3:228-234 (Pubitemid 46203125)
113. Didier A, Campos OR. A two-month comparison of salmeterol/ beclomethasone and slow-release terbutaline/budesonide in moderate asthma management. Clinical Drug Investigation 1997; Vol.14, issue 1:1-11. (Pubitemid 27338831)
114. Dorinsky P, Kerwin E, Schoaf L, Ellsworth A, Housse K. Effectiveness and safety of fluticasone propionate/salmeterol 250/50 mcg administered once daily to patients with persistent asthma [Abstract]. European Respiratory Journal 2004; Vol.24, issue Suppl 48:309s.
115. Faurschou P, Engel AM, Haanaes OC. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 1994; Vol.49, issue 10:827-832
116. Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, et al. Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy. Chest 2001; Vol.120, issue 2:423-430 (Pubitemid 32881257)
117. Fujimoto K, Komatsu Y, Yasuo M, Urushihata K, Kubo K. Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. Journal of Asthma. 2006; Vol.43, issue 7: 501-507 (Pubitemid 44567601)
118. GlaxoSmithKline. A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100 mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOVENT) 100 mcg twice daily and placebo twice daily, all via the DISKUS/ACUHALER as initial maintenance therapy in mild asthmatic subjects. GlaxoSmithKline Clinical Trial Register 2004.
119. GlaxoSmithKline. A 12 week, randomized, double-blind, parallel group study to compare the efficacy and safety of salmeterol/fluticasone propionate/GR106642X (25/50 μg x 2 inhalations) bid with fluticasone propionate (125 μg x 2 inhalations) bid in adolescent and adult patients with mild to moderate asthma. GlaxoSmithKline Clinical Trial Register 2005.
120. GlaxoSmithKline. Comparison of the efficacy and safety of Seretide and beclomethasone dipropionate plus montelukast in asthma. GlaxoSmithKline Clinical Trial Register 2005.
121. GlaxoSmithKline. A multi-centre, randomised, open-label, parallel group clinical trial to assess the efficacy and safety of salmeterol/fluticasone propionate combination product (2x 25/125μg/actuation, bd) via a hydrofluoroalkane metered-dose inhaler compared with salmeterol/fluticasone propionate accuhaler (50/250μg bd) in adult Chinese patients with mild to moderate asthma. GlaxoSmithKline Clinical Trial Register 2005.
122. GlaxoSmithKline. A randomized, double-blind clinical trial comparing the efficacy and safety of salmeterol xinafoate 42mcg bid plus fluticasone propionate 88mcg bid versus fluticasone propionate 220mcg bid alone in subjects with asthma not well controlled on fluticasone propionate 88mcg bid. GlaxoSmithKline Clinical Trial Register 2005.
123. GlaxoSmithKline. A repeat dose, randomised, double blind, twoway crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual fluticasone propionate 50 and salmeterol 50 DISKUS inhalers in subjects aged 18-55 years with mild asthma. GlaxoSmithKline Clinical Trial Register 2005.
124. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; Vol.344, issue 8917:219-224 (Pubitemid 24229008)
125. Grutters JC, Brinkman L, Aslander MM, van den Bosch JM, Koenderman L, Lammers JW. Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics. European Respiratory Journal 1999; Vol.14, issue 4:915-922 (Pubitemid 29519358)
126. House K, Dorinsky PM, Stauffer J, Schoaf L, Ellsworth A. The Safety of Fluticasone propionate/Salmeterol Diskus(R) in Pediatric Patients Ages 4-11 with Asthma [Abstract]. Chest 2004; Vol.126, issue 4 Suppl:911S-a.
127. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Annals of Allergy, Asthma, & Immunology 2004; Vol.92, issue 6:641-648 (Pubitemid 39243154)
128. Isabelle P, Bjamer D, Neuparth N, Desfougeres JL. Efficacy and safety of salmeterol/fluticasone combination 50/100mug bd via two different powder devices in children. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23 2001.
129. SAS40026. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SAS40026.pdf Acessed July 2008.
130. * Jarjour NN, Wilson SJ, Koenig SM, Laviolette M, Moore WC, Davis WB, et al. Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. J Allergy Clin Immunol 2006;118:44-52.
131. Johansson G, McIvor RA, D'Ambrosio FP, Gratziou C, James MH. Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clinical Drug Investigation 2001; Vol.21, issue 9:633-642 (Pubitemid 32937982)
132. Juniper EF, Jenkins C, Price MJ, James MH. Impact of inhaled salmeterol/ fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. American Journal of Respiratory Medicine 2002; Vol.1, issue 6: 435-440 (Pubitemid 37062710)
133. Kelsen SG, Church NL, Gillman SA, Lanier BQ, Emmett AH, Rickard KA, et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: A randomized clinical trial. Journal of Asthma 1999; Vol.36, issue 8: 703-715
134. Koopmans JG, Lutter R, Jansen HM, van der Zee JS. Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. Journal of Allergy & Clinical Immunology 2005; Vol.116, issue 5:1007-1013 (Pubitemid 41571780)
135. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Jr, et al. Long-Acting {beta}2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial. JAMA 2001; Vol.285, issue 20:2583-2593 (Pubitemid 32479898)
136. Lemanske RF, Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, et al. Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial. JAMA 2001; Vol.285, issue 20:2594-2603 (Pubitemid 32479899)
137. Lotvall J, Langley S, Woodcock A. Inhaled steroid/long-acting beta2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respiratory Research. Vol.7, 2006. Article Number: 110. Date of Publication: 18 AUG 2006.. (Pubitemid 44419886)
138. Lundback B, Jenkins C, Price MJ, Thwaites RM. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group. Respiratory Medicine 2000; Vol.94, issue 7:724-732 (Pubitemid 30458798)
139. Martinat Y, Desfougeres JL. Fixed-dose fluticasone-salmeterol combination: At least effective and better tolerated than open-dose combinations. [French]. Revue de Pneumologie Clinique 2003; Vol.59, issue 3:139-148
140. Morice A. An open labelled study to compare the systemic side effects of high dose fluticasone/salmeterol with that of high dose ciclesonide/salmeterol in symptomatic asthmatic patients. The North and South Bank Research and Development Consortium 2006; Vol.1/7/2007:Ongoing.
141. Murray JJ, Church NL, Anderson WH, Bernstein DI, Wenzel SE, Emmett A, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy & Asthma Proceedings 1999; Vol.20, issue 3:173-180
142. Nan SZ, Zheng JP, Humphries MJ, Xin D. Salmeterol/fluticasone propionate in a single inhaler is superior to budesonide alone in control of Chinese asthmatic adults: An open-label, randomised, 6- week study. Clinical Drug Investigation 2004; Vol.24, issue 10: 583-592 (Pubitemid 44283966)
143. Nathan RA, Mitchell D, Condemi J, Heller A, Schoaf L, Herrle M, et al. Cardiovascular and hypthalamic-pituitary-adrenal axis safety of fluticasone propionate/salmeterol hfa mdi in adolescent and adult patients with asthma. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23 2001.
144. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. Journal of Allergy & Clinical Immunology 2000; Vol.106, issue 6:1088-1095 (Pubitemid 32006262)
145. Nelson HS, Nathan RA, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. Medgenmed Computer File: Medscape General Medicine 2001; Vol.3, issue 4:3.
146. O'Byrne P. Efficacy of ciclesonide vs fixed combination of fluticasone propionate/salmeterol vs placebo in patients with mild persistent asthma (12 to 75 y). clinicaltrials.gov 2005.
147. O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; Vol.22, issue 12: 815-825 (Pubitemid 39158999)
148. Pauwels RA, Yernault JC, Demedt MG, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. American Journal of Respiratory & Critical Care Medicine 1998; Vol.157, issue 3 Pt 1:827-832
149. Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Annals of Allergy, Asthma, & Immunology 1999; Vol.82, issue 3:257-265 (Pubitemid 29141086)
150. Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. New England Journal of Medicine 2007; Vol.356, issue 20:2027-2039 (Pubitemid 46789893)
151. Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respiratory Medicine 2003; Vol.97, issue 3:234-241 (Pubitemid 36266879)
152. Rosenthal RR, Busse WW, Kemp JP, Baker JW, Kalberg C, Emmett A, et al. Effect of long-term salmeterol therapy compared with as needed albuterol use on airway hyperresponsiveness. Chest 1999; Vol.116, issue 3:595-602. (Pubitemid 29428472)
153. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Annals of Allergy, Asthma, & Immunology 1995; Vol.75, issue 5:423-428
154. SAM30002. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAM30002.pdf Accessed July 2008.
155. SAM30013. http://ctr.glaxowellcome.co.uk/Summary/fluticasone- salmeterol/III-SAM30013.pdf Accessed July 2008.
156. SAM40116. http://ctr.glaxowellcome.co.uk/Summary/fluticasone- salmeterol/III-SAM40116.pdf Accessed July 2008.
157. SAS30015. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/III- SAS30015.pdf Accessed July 2008.
158. Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. Family Practice 2007; Vol.24, issue 2:181-188 (Pubitemid 47079266)
159. Schlosser NJJ, Steinmetz KO, Aubier M, Gomez E, Wixon C. Evaluation of long term safety of salmeterol/fluticasone propionate (50/500μg) combination inhaler in patients with reversible airways obstruction. European Respiratory Journal. Supplement. 1998; Vol.12 Suppl 28:35S.
160. Scott C, Wu W, Ellsworth A, Crim C. Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children [Abstract]. European Respiratory Journal 2005; Vol.26, issue Suppl 49:Abstract No. 1057. (Pubitemid 41207836)
161. SLGA5021. http://ctr.gsk.co.uk/Summary/fluticasone- salmeterol/IV- SLGA5021.pdf Accessed August 11th 2008.
162. Tonnel AB, Desfougeres JL. Efficacy and acceptability of the fixed fluticasone + salmeterol combination in the treatment of acute asthma attacks. Results of a one-year comparative study. [French]. Revue de Pneumologie Clinique 2004; Vol.60, issue 4:209-216
163. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate 50/100 microg in combination in a Diskus inhaler Seretide is effective and safe in children with asthma. Pediatric Pulmonology 2000; Vol.30, issue 2:97-105.
164. Van Noord JA, Schreurs AJM, Mol SJM, Mulder PGH. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; Vol.54, issue 3:207-212 (Pubitemid 29110499)
165. Vermetten FA, Boermans AJM, Luiten WD, Mulder PGH, Vermue NA. Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. Journal of Asthma 1999; Vol.36, issue 1:97-106.
166. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. American Journal of Respiratory &Critical Care Medicine 1996; Vol.153, issue 5:1481-1488 (Pubitemid 26141329)
167. You-Ning L, Humphries M, Du X, Wang L, Jiang J. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. International Journal of Clinical Practice 2005; Vol.59, issue 7:754-759 (Pubitemid 43904538)
168. Zhong N. Comparison of the effectiveness and safety in use of salmeterol/fluticasone delivered together in a Seretide Acuhaler or salmeterol and fluticasone delivered separately for patients with moderate or severe asthma. Chinese Journal of Tuberculosis and Respiratory Disease 2002; Vol.25, issue 6:371.
169. Zhong NS, Zheng JP, Cai BQ, Xie CM, Sun TY, Wang DQ, et al.[Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhalar compared to budesonide turbuhalar in the control of adult asthma.]. Zhonghua Jie He He Hu Xi Za Zhi 2005; Vol.28, issue 4:233-237
170. Altman DG, Bland JM. Statistics Notes: Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
171. Anderson GP. Current issues with beta(2)-adrenoceptor agonists - Pharmacology and molecular and cellular mechanisms. Clinical Reviews in Allergy & Immunology 2006; Vol.31, issue 2-3:119-130 (Pubitemid 44804943)
172. Arnold JMO, Oconnor PC, Riddell JG,Harron DWG, Shanks RG, McDevitt DG. Effects of the beta-2-adrenoceptor antagonist ici-118, 551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. British Journal of Clinical Pharmacology 1985; Vol.19, issue 5:619-630
173. Barnes PJ. Beta-adrenoceptors on smooth-muscle, nerves and inflammatory cells. Life Sciences 1993; Vol.52, issue 26:2101-2109
174. Barnes PJ. Beta-adrenergic receptors and their regulation. American Journal of Respiratory and Critical Care Medicine 1995; Vol.152, issue 3:838-860
175. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, et al. Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events. Ann Intern Med 2008; Vol.149, issue 1:33-42. (Pubitemid 351931131)
176. Beach JR, Young CL, Stenton SC, Avery AJ, Walters EH, Hendrick DJ. A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulm-Pharmacol 1992;5(2):133-135
177. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; Vol.49, issue 8:771-774 (Pubitemid 24250233)
178. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta-2-receptor stimulation by circulating epinephrine. New England Journal of Medicine 1983; Vol.309, issue 23:1414-1419
179. Burgess CD, Windom HH, Pearce N, Marshall S, Beasley R, Siebers RWL, et al. Lack of evidence for beta-2 receptor selectivity - a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma. American Review of Respiratory Disease 1991; Vol.143, issue 2:444-446
180. Burggraaf J, Westendorp RGJ, in't Veen J, Schoemaker RC, Sterk PJ, Cohen AF, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; Vol.56, issue 7:567-569
181. Cates Christopher J, Cates Matthew J, Lasserson Toby J. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006923.pub2; : CD006923]
182. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2; : CD006363]
183. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858. CD006924.pub2; : CD006924]
184. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; Vol.342, issue 8875:833-837
185. Collins JM, McDevitt DG, Shanks RG, Swanton JG. Cardio-toxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1969; Vol.36, issue 1:35-&.
186. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1983 - case-control study. Lancet 1989; Vol.1, issue 8644:917-922
187. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta- 2 agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003137.pub3; : CD003137]
188. GlaxoSmithKline. Benefit Risk Assessment of Salmeterol for the Treatment of Asthma in Adults and Children. www.fda.gov/ohrms/dockets/ac/08/briefing/2008- 4398b1-04-GSK.pdf Accessed February 24th 2009.
189. Giembycz MA, Newton R. Beyond the dogma: novel β2-adrenoceptor signalling in the airways. European Respiratory Journal 2006;27 (6):1286-1306. (Pubitemid 44920003)
190. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7 - a further case-control study. Thorax 1991; Vol.46, issue 2:105-111
191. Greenstone IR, Ni Chroinin M, Masse V, Danish A, Magdalinos H, Zhang X, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005533; : CD005533]
192. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; Vol.55, issue 8:650-656 (Pubitemid 30468219)
193. Hall JA, Petch MC, Brown MJ. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2-adrenoceptors in the human-heart. Circulation Research 1989; Vol.65, issue 3: 546-553
194. Hanania NA, Sharfkhaneh A, Barber R, Dickey BF. beta-agonist intrinsic efficacy - Measurement and clinical significance. American Journal of Respiratory and Critical Care Medicine 2002; Vol.165, issue 10:1353-1358 (Pubitemid 34522936)
195. Hanania NA, Moore RH, Zimmerman JL, Miller CT, Bag R, Sharafkhaneh A, et al. The role of intrinsic efficacy in determining response to beta(2)-agonist in acute severe asthma. Respiratory Medicine 2007; Vol.101, issue 5:1007-1014 (Pubitemid 46505985)
196. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al. Tolerance to beta-agonists during acute bronchoconstriction. European Respiratory Journal 1999; Vol.14, issue 2:283-287
197. Hancox RJ. Interactions between corticosteroids and beta2-agonists. Clinical Reviews in Allergy & Immunology 2006; Vol.31, issue 2-3: 231-246 [: (Print)]
198. Haney S,Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clinical Reviews in Allergy & Immunology 2006; Vol.31, issue 2-3:181-196
199. Harvey JE, Tattersfield AE. Airway response to salbutamol - effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982; Vol.37, issue 4:280-287
200. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Clinical safety data management: Definitions and standards for expedited reporting. http: //www.fda.gov/cder/guidance/iche2a.pdf 1995.
201. Jaeschke R, O'Byrne PM, Parameswaran N, et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis.. Pol Arch Med Wewn 2008; Vol.118, issue 11:627-635.
202. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, et al. The Safety of Long-Acting Beta-Agonists among Patients with Asthma Using Inhaled Corticosteroids: Systematic Review and Meta-analysis. Am. J. Respir. Crit. Care Med. 2008; Vol.178, issue 10:1009-1016
203. Jones SL,Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. European Respiratory Journal 2001; Vol.17, issue 3:368-373 (Pubitemid 32600603)
204. Lee DKC, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. British Journal of Clinical Pharmacology 2003; Vol.56, issue 5:494-500.
205. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high-dose inhaled salbutamol in asthmatics. American Review of Respiratory Disease 1989; Vol.140, issue 3:586-592
206. Lipworth BJ, McDevitt DG. Inhaled beta-2-adrenoceptor agonists in asthma - help or hindrance. British Journal of Clinical Pharmacology 1992; Vol.33, issue 2:129-138
207. Lipworth BJ. Airway subsensitivity with long-acting beta 2-agonists: Is there cause for concern?. Drug Safety 1997;16(5):295-308.
208. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; Vol.117, issue 1:156-162 (Pubitemid 30053635)
209. McDevitt DG, Shanks RG, Swanton JG. Further observations on cardiotoxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1974; Vol.50, issue 3:335-344
210. Morrison KJ, Gao Y, Vanhoutte PM. Beta-adrenoceptors and the epithelial layer in airways. Life Sciences 1993; Vol.52, issue 26: 2123-2130
211. Nelson HS, Raine D, Doner HC, Posey WC. Subsensitivity to bronchodilator action of albuterol produced by chronic administration. American Review of Respiratory Disease 1977; Vol.116, issue 5: 871-878 (Pubitemid 8135585)
212. Ni Chroinin M, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults (Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD005307; : CD005307]
213. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005535; : CD005535]
214. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. American Journal of Respiratory and Critical Care Medicine 1999; Vol.160, issue 1:244-249 (Pubitemid 29326095)
215. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, et al. Case-control study of prescribed fenoterol and death from asthma in new-zealand, 1977-1981. Thorax 1990; Vol.45, issue 3:170-175
216. Pearce N. Adverse reactions: the Fenoterol story. 1. Auckland: Auckland University Press, 2007:215. [: 9781869403744]
217. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144 (12):904-912
218. Sears M, Rea H, Rothwell R, O'Donnell T, Holst P, Gillies A, et al. Asthma mortality: comparison between New Zealand and England. British Medical Journal 1986;293(6558):1342-1345 (Pubitemid 17181798)
219. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial-asthma. Lancet 1990; Vol.336, issue 8728:1391-1396
220. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting {beta}-agonists: A review of formoterol safety data from asthma clinical trials. European Respiratory Journal 2008:09031936.00145006.
221. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest 2006;129:15-26.
222. Castle W, Fuller R, Hall J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. British Medical Journal 1993;306:1034-1037 (Pubitemid 23105961)
223. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. British Medical Journal 1968; Vol.1, issue 5588: 335-&.
224. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004/04/30 2004; Vol.23, issue 9:1351-1375 [0277-6715: (Print)]
225. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta(2) agonists. Thorax 2001; Vol.56, issue 7:529-535 (Pubitemid 32588531)
226. vanNoord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. European Respiratory Journal 1996; Vol.9, issue 8:1684-1688
227. Walters EH, Walters JAE, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003901]
228. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for stable chronic asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: DOI: 10.1002/14651858.CD001385.pub2]
229. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics - development of subsensitivity with long-term administration. Journal of Allergy and Clinical Immunology 1982; Vol.70, issue 6:417-422
230. Weiss KB. Drug safety and salmeterol: the controversy continues. Ann Intern Med. 2008/06/05 2008; Vol.149, issue 1:56-57 [1539- 3704: (Electronic)]
231. Wilson JD, Sutherland DC, Thomas AC. Has the change to betaagonists combined with oral theophylline increased cases of fatal asthma. Lancet 1981; Vol.1, issue 8232:1235-1237 (Pubitemid 11104686)
232. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; Vol.336, issue 8728:1396-1399
233. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta(2)-agonist. American Journal of Respiratory and Critical Care Medicine 1996; Vol.154, issue 6:1603-1607 (Pubitemid 26424922)